Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02641093 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
A Phase 2 study of Head and Neck Cancer, sponsored by Trisha Wise-Draper.
- Active
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 6
- Study locations
NCT02641093: Active Phase 2 study of Head and Neck Cancer, sponsored by Trisha Wise-Draper.
NCT02641093 is a Phase 2 study of Head and Neck Cancer that is active but no longer recruiting, run by Trisha Wise-Draper. The registered enrollment target is 96 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (63% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02641093, a Phase 2 study of Head and Neck Cancer, is active but no longer recruiting, sponsored by Trisha Wise-Draper.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for head and neck cancer. The standard of care treatment will include surgery followed by radiation for 6 weeks. Some patients may also receive cisplatin as standard of care once a week for 6 weeks if the cancer is found to be "high risk". High risk includes cancer that was not completely removed (positive margins) or cancer that has invaded through the outer lining of your lymph nodes.
Primary Outcome
Number of participants with treatment related adverse effects as assessed using CTCAE v4.0 of pembrolizumab when combined with radiation alone and chemoradiation. Compared as percentage of grade 3 and 4 adverse events with historical control percentages.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- RADIATION Radiation Therapy
- PROCEDURE Surgery
Study Locations (6)
Ohio
- University of Cincinnati Medical Center - Cincinnati
- Ohio State University - Columbus
Kentucky
- University of Louisville - James Graham Brown Cancer Center - Louisville
Michigan
- University of Michigan - Ann Arbor
South Carolina
- Medical University of South Carolina - Charleston
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2016-01 |
| Est. Completion | 2025-11-02 |
| Phase | Phase 2 |
What the registry record for NCT02641093 still lists
NCT02641093 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02641093 lists 6 locations in 5 states (Ohio, Kentucky, Michigan).
Frequently Asked Questions
What is clinical trial NCT02641093 about?
NCT02641093 is a clinical study titled "Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma". The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for head and neck cancer. The standard of care treatment will include surgery followed by radiation for 6 weeks....
What is the current status of trial NCT02641093?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2016-01. Estimated completion is 2025-11-02.
What conditions does trial NCT02641093 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT02641093?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Radiation Therapy (RADIATION), Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT02641093?
This trial is sponsored by Trisha Wise-Draper, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02641093 being conducted?
This trial has 6 study locations across Kentucky, Michigan, Ohio, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02641093's enrollment target sits among peer trials
96 90th of 250 higher than 161 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia